| 胰高血糖素样肽1受体激动剂在2型糖尿病治疗中的研究进展 |
| |
| 引用本文： | 秦荣浦,杨宇峰.胰高血糖素样肽1受体激动剂在2型糖尿病治疗中的研究进展[J].国际生物制品学杂志,2016(1):44-48. |
| |
| 作者姓名： | 秦荣浦 杨宇峰 |
| |
| 作者单位： | 200052,上海生物制品研究所有限责任公司第二研究室 |
| |
| 摘 要： | 胰高血糖素样肽1受体激动剂（glucagon‐like peptide‐1 receptor agonist ，GLP‐1RA）是近年来2型糖尿病药物开发领域的研究热点。作为一种降血糖药物，GLP‐1RA 在增强患者血糖调控能力的同时，还能降低患者低血糖风险，减轻体重，保护心血管系统。此文对已上市和部分正处于临床试验阶段的 GLP‐1RA 的疗效及安全性做一综述，并对 GLP‐1RA 药物的发展趋势进行探讨。
|
| 关 键 词： | 胰高血糖素样肽 1 受体激动剂 糖尿病 2 型 降血糖药 |
Research progress of glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes mellitus |
| |
| Abstract: | Glucagon‐like peptide‐1 receptor agonist (GLP‐1RA ) has become an important thera‐peutic approach for type 2 diabetes .Evidence suggests that GLP‐1RA can improve glycemic control while decrease risk of hypoglycemia ,reduce body weight ,and protecting cardiovascular system .This review presents the efficacy and tolerability of various GLP‐1RA drugs available for clinical practice or under clinical trials ,and concludes that optimized usage of GLP‐1RA drugs could represent a significant para‐digm shift for the treatment of type 2 diabetes . |
| |
| Keywords: | Glucagon-like peptide-1 receptor agonist Diabetes mellitus type 2 Hypoglycemic agents |
| 本文献已被 万方数据 等数据库收录！ |
